Navigation Links
Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
Date:3/1/2011

s proprietary endothelial cell-based platform to prevent solid tumor growth, cancer recurrence and metastatic disease.

About Pervasis Pervasis Therapeutics, Inc. is a clinical stage company that is developing groundbreaking endothelial cell-based therapies designed to regulate the body's natural healing and repair processes in various critical therapeutic areas. The company has initially focused on developing therapies to improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stent placements, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs. The company's lead program, Vascugel®, has demonstrated proof of concept and safety in two Phase 2 clinical trials. Pervasis is also applying its endothelial cell-based platform technology to develop an oncology therapy focused on preventing solid tumor growth, cancer recurrence and metastatic disease, as well as products for inflammatory disease and orthopedic injury.

Pervasis is a privately held company with funding from Flagship Ventures, Polaris Venture Partners, Highland Capital Partners and the Richter Family Fund. For more information, please visit www.pervasistx.com.  

This news release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the timing of clinical trials, the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in clinical trials and the risk that the company will not obtain approval to market its products.

(1)  Dixon et al. DAC Study Group. Effect of dipyridamole plus aspirin on he
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
2. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
3. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
4. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
5. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
6. Mylan Receives Approval for Generic Version of Neurontin® Capsules
7. Elektas Oncology-Specific MOSAIQ Receives Complete ONC-ATCB EMR Certification
8. ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software
9. Vapotherm® Receives FDA 510(k) Clearance for Flowrest® Homecare Device
10. Delcath Systems Receives Refusal to File Letter From FDA
11. Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... YORK , Feb. 27, 2015  Pomerantz LLP ... Pharmaceuticals, Inc. ("Vitae" or the "Company") (NASDAQ: ... Robert S. Willoughby at rswilloughby@pomlaw.com or ... Vitae and certain of its officers and/or directors have ... Act of 1934.  On February 27, ...
(Date:2/27/2015)... -- Following a bipartisan vote in the House Ways ... Medicare DMEPOS Competitive Bidding Improvement Act of 2015 ... a statement praising the Committee,s work and pushing ... "Today,s mark-up of the Competitive Bidding Improvement ... is a critical step forward for this bipartisan, ...
(Date:2/27/2015)... 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... pro forma net operating loss (NOL) guidance and its ... position.  Isis, significantly improved financial results were due in ... payments the Company received from its partners.  Isis, pro ... nearly 60% improvement over its 2013 NOL of $40.2 ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17
... Calif., Dec. 21, 2010 Based on its ... Frost & Sullivan recognizes Cambridge, Mass.-based Semprus BioSciences ... Year Award for Surface Functionalization Technologies . The ... modification designed to reduce the complications associated with ...
... 21, 2010 Generational Equity, a leading advisor ... acquisitions, strategic growth initiatives, business valuation and exit ... Inc. dba Remedies Pharmacy, headquartered in Carrollton, Missouri, ... on October 26, 2010.  Managing Director, Terry Mackin ...
Cached Medicine Technology:Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences 2Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences 3Generational Equity Announces Sale of B-Pharm, Inc. dba Remedies Pharmacy to a Private Investment Group 2
(Date:2/28/2015)... 2015 Gerald “Solutionman” Haman surveyed over ... barriers to innovative thinking. “The #1 block was ... of tools,” reports Haman, who created the Thinkubator Innovation ... people felt that they did not have enough time ... resources to stimulate innovation. , Solutionman’s monthly “Accelerating Innovation ...
(Date:2/28/2015)... The Classic Denture Center , ... special. Throughout all of March patients can receive ... service can help overall mouth health and ... may notice certain symptoms that suggest the denture teeth ... include: , 1.    Pain, clicking, and popping in the joints, ...
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law Corporation recently announced ... They stated that in many cases, missing an important time ... Many a time, delays in making an injury claim can ... As a result, experts at Jiwa Law Corporation suggest that ... injury lawyer in order to know more about their rights. ...
(Date:2/28/2015)... 2015 For those people who are ... Mesothelioma Applied Research Foundation (Meso Foundation) will ... 3, starting at 9:30 AM. , The live broadcast ... broadcast can be accessed through any browser on a ... The Symposium is a unique event that covers important ...
(Date:2/28/2015)... 28, 2015 National Sales ... sales, marketing and supply chain management for consumer ... is bringing its award winning solutions for thinning-damaged ... products are specifically created to combat thinning-damaged hair. ... is committed to marrying science with nature to ...
Breaking Medicine News(10 mins):Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... 31 On April 1, the federal cigarette tax will ... pack, to fund the expansion of the State Children,s Health ... A new survey shows that the April 1st federal ... concerns for smokers and will change their current smoking habits.(2)The ...
... Health today announced that its Clinical and Medical ... off later this year as CareFusion Corporation, will ... six months and eliminate an additional 500 positions ... addition, Cardinal Health will implement cost control measures ...
... Scientific Company (ESC) is demonstrating a critical technology ... which link healthcare enterprises into the Nationwide Health ... Management Systems Society (HIMSS) conference, April 5-8, 2009. ... problem healthcare enterprises face in providing interoperable, authorized ...
... testimony today before the U.S. Senate Committee on Agriculture, ... revise school food nutrition standards so that more nutritious ... federal nutrition standards for foods sold outside of the ... updated since the late 1970s. , ...
... Infusing cells into damaged area helped restore blood flow, ... Treating a heart attack with the patients, own bone ... and may help reduce long-term complications, a new U.S. ... underwent angioplasty and stent placement after a heart attack. ...
... for dieters who face food challenges in the break room every ... shows that our resistance gets a boost after we,ve just ... a real one for many of us. It is all too ... with their desire to smoke or to drink alcohol or to ...
Cached Medicine News:Health News:Federal Cigarette Tax Increase and Current Economy Will Change Smoker's Habits 2Health News:Federal Cigarette Tax Increase and Current Economy Will Change Smoker's Habits 3Health News:Federal Cigarette Tax Increase and Current Economy Will Change Smoker's Habits 4Health News:Cardinal Health to Reduce Workforce to Respond to Economic Conditions 2Health News:Cardinal Health to Reduce Workforce to Respond to Economic Conditions 3Health News:Edmond Scientific Company Demonstrates RHIO/HIE Data Security and Privacy Solution for the NHIN at Annual HIMSS Conference, Chicago '09 2Health News:Mars Snackfood Urges U.S. Congress to Update National School Nutrition Standards 2Health News:Mars Snackfood Urges U.S. Congress to Update National School Nutrition Standards 3Health News:Patient's Own Stem Cells Might Treat Heart Attack 2Health News:Learning curve: Tricks to resist temptation 2
... system introduces a new level ... microsurgical instrumentation. It has an ... with advanced microcomputer control of ... operate with a full range ...
... The Horizon Phacoemulsification System ... segment surgical system. Lightweight ... high-end performance and features ... It also provides all ...
Phaco-emulsification systems CV series...
Phacoemulsification system is a complete anterior segment surgical instrument. Its simplified design and unique innovations provide optimal surgical performance....
Medicine Products: